Poster Session 2 - Saturday, August 27, 2016
LOCATION: EXHIBIT HALL
PRESENTING AUTHOR STAND BY TIME: 10:30 - 11:00 AND 16:15 - 16:45

**SCLC, MESOTHELIOMA, THYMOMA**

**P2.01** LUME-Meso: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Malignant Pleural Mesothelioma
Giorgio Scagliotti, IT

**P2.02** Thymic Malignancies. A Single Institution Series from 2006-2016
Flavio Cabral, BR

**P2.03** Treatment of Malignant Pleural Mesothelioma beyond First-Line among Hispanics (MeSO-CLiCaP)
Luis Corrales-Rodriguez, CR

**P2.04** Characteristics and Long Term Outcomes of Advanced Pleural Mesothelioma in Latin America (MeSO-CLiCaP)
Oscar Arrieta, MX

**P2.05** The Synthetic Peptide CIGB-300 Inhibits NF-kB Translocation Affecting the Survival and Chemoresistance of NSCLC Cell Lines
Stéfano Cirigliano, AR

**P2.06** Exosomal miRNA Analysis in Non-Small Cell Lung Cancer: New Liquid Biomarker?
Christian Rolfo, BE

**P2.07** Evaluation of Different Exosomal RNA Isolation Methods in NSCLC Liquid Biopsies
Christian Rolfo, BE

**P2.08** Gene Fusions Detected in Non-Small Cell Lung Carcinoma (NSCLC) and Small Cell Lung Carcinoma (SCLC)
David Arguello, US

**P2.09** cMET in NSCLC: Expression, Amplification and Mutations
Christian Rolfo, BE

**P2.10** Clinical and Pathological Characteristics of ALK Positive Lung Cancer Patients. Instituto Oncológico Nacional - Panamá
Taysser Sowley D, PA

**P2.09** cMET in NSCLC: Expression, Amplification and Mutations
Christian Rolfo, BE

**P2.10** Clinical and Pathological Characteristics of ALK Positive Lung Cancer Patients. Instituto Oncológico Nacional - Panamá
Taysser Sowley D, PA

**P2.12** Treatment Response in Patients with ALK Immunohistochemistry (IHC) Positive with FISH Negative
Manglio Rizzo, AR

**PATHOLOGY**

**P2.13** Testing Profiles in NSCLC Biopsy Samples: Multi-Institutional Study in Cordoba
NORMA Pilnik, AR

**P2.14** Lung Cancer as Second Primary Cancer in Two Patients in a Reference Hospital in Latin America: A Case Report
Liliana Fernandez Trujillo, CO

**P2.15** Treatment Outcome of Metastatic Breast Angiosarcoma to the Lung, in a Reference Hospital in Latin America: A Case Report
Liliana Fernandez Trujillo, CO

**P2.16** Atypical Adenomatous Hyperplasia (AAH) in a Patient with a Primary Carcinoid Lung Tumor: Case-Report
Liliana Fernandez, CO

**P2.17** Incidence Of Non-small Cell Lung Cancer Biomarkers in Panama; Demographyc, Clinic and Histopathological Features
Ruth Vergara, PA
**P2.18 Rapid On-Site Evaluation (ROSE) Technique: Experience in the Pulmonology Unit of a Reference Hospital in Latin America**
Liliana Fernandez, CO

**P2.18 (also presented as PD1.04)**
Infrequent Staining Patterns in ALK Immunohistochemistry: Correlation with Fish Analysis
Paola De La Iglesia, AR

**P2.20 Malignant Obstruction of the Central Airway by an EBV(+) Diffuse Large B-Cell Lymphoma: An Unusual Presentation**
Liliana Fernandez, CO

**BRONCHOSCOPY**

**P2.21 Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Experience in a Reference Hospital in Latin America**
Liliana Fernandez, CO

**P2.22 Therapeutic Bronchoscopy in Multimodal Therapy for the Management of Central Airway Obstruction in Latin America**
Liliana Fernandez, CO

**P2.23 Effectiveness of Methylnaltrexone Bromide as a Treatment for Opioid-Induced Constipation in NSCLC Patients**
Ioannis Dimitroulis, GR

**P2.24 Pulmonary-Epithelioid Hemangioendothelioma: A Case Report of Spontaneous Regression**
Raquel Rojas-Vigott, CR

**IMMUNOTHERAPY**

**P2.34 Vaxira and CIMAvax-EGF Therapeutic Vaccines Combination in the Advanced NSCLC Treatment**
Amparo Macias, CU

**P2.35 Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis**
Clarissa Mathias, BR

**P2.36 Nivolumab (nivo) in Patients (pts) with Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (Mets)**
Gilberto Lopes, BR

**P2.37 A Case of Immune-Mediated Pneumonitis?**
Cláudia Matos, PT

---

**SUPPORTIVE CARE AND OTHERS**

**P2.26 Reference to Palliative Care in Patients with Advanced Lung Cancer Treated with Systemic Therapy. Ion, Panamá**
Joel Moreno-Ríos, PA

**P2.27 Blood Supplement Research of the Percutaneous Inoculated Canine Transmissible Venereal Tumor Lung Cancer Model**
Xiao An, CN

**P2.28 Image-Guided Radiofrequency Ablation of Lung Metastases. A Single Cancer Center Experience in Panama**
Jose Pinto Llerena, PA

**P2.29 An Approach to Ensure Adequate Intake of Nutrients for Patients with Lung Cancer**
Julissa Luvian-Morales, MX

**P2.31 Understanding Factors Influencing Self-Referral of Patients from Resource-Limited Institutions Seeking Lung Cancer Care**
Jorge Rios, US

**P2.32 Survival Assessment of Non-Small Cell Lung Neoplasia Patients in Advanced Stage Treated with the CIMAvax-EGF Vaccine**
Carlos Cobian, CO

**P2.33 Safety Profile of Nivolumab Administered as 30-Minute (Min) Infusion: Analysis of Data from CheckMate 153**
Eduardo Richardet, AR

---

Saturday, August 27, 2016
P2.38 Nivolumab in Clinical Practice: Real World Experience in an Argentina Oncologic Center
Manglio Rizzo, AR

P2.39 Long-Term OS for Patients with Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab
Suresh Ramalingam, US

P2.40 CIMAavaxEGF Vaccine for the Treatment of Real-World NSCLC Patients.
Maurenis Hernandez, CU

P2.41 (also presented as PD1.06)
Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment
Roy Herbst, US

P2.42 An Immunotherapy Approach to Overcoming Resistance to Second and Third Generation EGFR Inhibitors
Yosef Yarden, IL

P2.43 Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894)
Gilberto De Lima Lopes, BR

P2.44 An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a Biomarker
Gilberto Lopes, BR

P2.45 An Estimate of the Economic Impact of Treatment of NSCLC with Immunotherapy Relative to PD-L1 Expression in Brazil
Gilberto Lopes, BR

P2.46 (also presented as PD1.01)
LCSS as a Marker of Treatment Benefit with Nivolumab vs Docetaxel in Pts with Advanced Non-Squamous NSCLC from CheckMate 057
Clarissa Mathias, BR

The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis
Gilberto Lopes, BR